» Articles » PMID: 39458511

Highland Barley Alleviates High-Fat Diet-Induced Obesity and Liver Injury Through the IRS2/PI3K/AKT Signaling Pathway in Rats

Overview
Journal Nutrients
Date 2024 Oct 26
PMID 39458511
Authors
Affiliations
Soon will be listed here.
Abstract

Highland barley (HB) consumption offers numerous health benefits; however, its impact on glycolipid metabolism abnormalities induced by a high-fat diet remains unclear. Consequently, this study aimed to investigate the therapeutic effects and underlying molecular mechanisms of HB in the context of obesity; Rats were fed either a high-fat diet (HFD) to induce obesity or a standard diet (SD) for six weeks. The rats in the HFD group were randomly assigned into five groups: HFD+HFD, HFD+SD, and low (30%), medium (45%), and high (60%) doses of the HB diet for an additional ten weeks. Analyses of serum lipid profiles, liver histology, transcriptomes, and untargeted metabolomes were conducted; HB intake resulted in decreased weight gain, reduced feed intake, lower serum triglyceride and cholesterol levels, and diminished hepatic lipid accumulation. It also improved insulin and fasting blood glucose levels, and antioxidant capacity in the HFD-fed rats. Transcriptome analysis revealed that HB supplementation significantly suppressed the HFD-induced increase in the expression of Angptl8, Apof, CYP7A1, GDF15, Marveld1, and Nr0b2. Furthermore, HB supplementation reversed the HFD-induced decrease in Pex11a expression. Untargeted metabolome analysis indicated that HB primarily influenced the pentose phosphate pathway, the Warburg effect, and tryptophan metabolism. Additionally, integrated transcriptome and metabolome analyses demonstrated that the treatments affected the expression of genes associated with glycolipid metabolism, specifically ABCG8, CYP2C12, CYP2C24, CYP7A1, and IRS2. Western blotting confirmed that HB supplementation impacted the IRS2/PI3K/AKT signaling pathway; HB alleviates HFD-induced obesity and liver injury in an obese rat model possibly through the IRS2/PI3K/Akt signaling pathway.

References
1.
Yu Cai Lim M, Ho H . Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. Biochem Pharmacol. 2023; 220:115985. DOI: 10.1016/j.bcp.2023.115985. View

2.
Assadi A, Zahabi A, Hart R . GDF15, an update of the physiological and pathological roles it plays: a review. Pflugers Arch. 2020; 472(11):1535-1546. DOI: 10.1007/s00424-020-02459-1. View

3.
Obadi M, Sun J, Xu B . Highland barley: Chemical composition, bioactive compounds, health effects, and applications. Food Res Int. 2021; 140:110065. DOI: 10.1016/j.foodres.2020.110065. View

4.
Morton R, Mihna D . Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma. J Lipid Res. 2022; 63(2):100166. PMC: 8953654. DOI: 10.1016/j.jlr.2021.100166. View

5.
Wang H, Wang J, Zhu Y, Yan H, Lu Y . Effects of Different Intensity Exercise on Glucose Metabolism and Hepatic IRS/PI3K/AKT Pathway in SD Rats Exposed with TCDD. Int J Environ Res Public Health. 2021; 18(24). PMC: 8701401. DOI: 10.3390/ijerph182413141. View